In December 2021, PD Neurotechnology® has reached the milestone of 150 trained physicians in the usage of PDMonitor®. In 2020-2021, PD Neurotechnology® has successfully organized 6 in person PDMonitor® Induction and Usage training sessions in Athens, Thessaloniki, London, Lund and 4 Webex trainings at the company’s R&D and Production facility in Ioannina, together with more than 10 additional specialty center virtual sessions.
More than 150 Physicians from Cyprus, France, Germany, Greece, Ireland, Israel, Italy, Russia, Spain, Sweden, Turkey, UK and US as well as Physiotherapists, PD Nurses and PD Researchers attended the 2-4h sessions offered by Professor Konitsiotis and other members of PD Neurotechnology® and were accordingly certified to use PDMonitor® in their daily practice.
Professor Konitsiotis showed among others a number of interesting case studies and the Physician Tool, a web-based application used by the Physicians to view and download patient reports with a comprehensive and objective assessment of the disease symptoms. It serves as a patient management tool, while at the same time it stores patient data for 10 years, as an Electronic Patient Record. Professor Konitsiotis commented:
“Through these trainings we have the chance to communicate with movement disorders specialists, exchange views and drive together a true paradigm shift in the Parkinson’s Disease management. Demand for these trainings has surpassed our expectations, leading to a new generation of Parkinson’s Disease specialists, digitally savvy, closely linked to their patients.”
You can find the press release here.
PD Neurotechnology Ltd.is an awarded, high-tech medical device company, founded in London, UK in 2015, certified with ISO 9001:2015, ISO 27001:2013, ISO 27701:2019 and ISO 13485:2016. Its first product, PDMonitor is a CE marked, Class IIa medical device, a digital, noninvasive, continuous monitoring system and management tool, used by patients with Parkinson’s Disease, which enables an accurate motor symptom evaluation, coupled with information on lifestyle and drug adherence. A web application offers the treating physician a comprehensive and objective view of the patient status and supports the assessment of the disease stage and prompt and optimal modification of the treatment. PDMonitor® is currently marketed in 10 European countries, soon to be available in the US, post FDA clearance.